Prevention and treatment of itch with an mrgpr antagonist
AssigneeThe General Hospital Corporation
InventorsEthan A. Lerner, Eshan Azimi, Vemuri B. Reddy
Life of this patent
Estimating the term…
Abstract
Embodiments described herein relates to compositions and methods of preventing and/or treating itch in a subject using a therapeutically effective amount of a MRG receptor antagonist. e.g., a tripeptide QWF. In one embodiment, the itch is a non-histamine mediated itch.
Claims37
-25. (canceled)
A method of preventing or treating itch or treating a disease or disorder having itch as a symptom or sensation associated with a disease or disorder in a subject, the method comprising administering a therapeutically effective amount of an MRG receptor antagonist to the subject.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of preventing or treating one or more sensation arising from an irritation, urticaria, pain, inflammation, asthma, allergy, allergic rhinitis, inflammatory bowel disease and irritable bowel disease in a subject, the method comprising administering a therapeutically effective amount of an MRG receptor antagonist to the subject.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.